Nantong Jinglan Biotech breaks ground on new facility
Located in the Nantong National High-tech Industrial Development Zone (NHIZ), Nantong Jinglan Biotechnology Co broke ground for its new production facility on Nov 7.
The progress marks the company transition from a "talent project" to an "industrial project" in just six years, exceeding the biopharmaceutical industry's average conversion time of over eight years.
Jinglan Biotech is China's first company focused on R&D and manufacturing of third-party medical testing quality control products. It established itself in NHIZ in 2019 as a talent project, initially with only four team members.
Over the years, the company has fully covered medical quality control product categories, mastered essential storage technologies, and improved self-sufficiency in the domestic IVD supply chain. It has developed into a mature enterprise with over 50 employees and annual sales exceeding 100 million yuan ($14.10 million). The company has also gained the international accreditation of China National Accreditation Service for Conformity Assessment.
The new project involves a total investment of 500 million yuan, with Phase 1 costing 200 million yuan and covering an area of 23 mu (1.53 hectares). Once fully operational, it is expected to produce 2.5 million bottles of IVD quality control products each year, resulting in sales of 500 million yuan and supporting the area's high-quality development.
